Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ER tapentadol data in diabetic peripheral neuropathy support J&J sNDA

This article was originally published in Scrip

Executive Summary

A bid by Janssen Pharmaceuticals, a Johnson & Johnson company, to get FDA approval for the use of Nucynta ER (tapentadol) extended-release tablets in managing pain associated with chronic diabetic peripheral neuropathy (DPN) has been given a welcome boost by additional Phase III data.